Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of...
Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy...
Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. These awards across several geographies recognize the progress represented by Voranigo® for patients...
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global...
Binance Becomes First Crypto Exchange To Secure a Global License Under ADGM Framework, Setting a New Standard in Digital-Asset Regulation
ABU DHABI, UAE, Dec. 8, 2025 /PRNewswire/ -- Binance, the world's largest cryptocurrency exchange by trading volume and users, today announced a landmark regulatory achievement: The Financial Services Regulatory Authority (FSRA) of ADGM, the...
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully...
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA)...
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development
HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis Mean dysmenorrhea pain score reduced by 42% Mean non-menstrual chronic pelvic pain score reduced by 52% Most patients maintained normal...
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug...
Recurrent Energy Secures Development Consent Order for the Tillbridge Solar and Battery Storage Project in the UK
The project combines 800 MW of solar PV and 500 MW / 1,000 MWh of battery energy storage, marking a major milestone in Recurrent Energy's UK growth strategy. KITCHENER, ON, Dec. 2, 2025 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian...